Centene (0HVB) AI Stock Analysis

0 Followers

Centene

(LSE:0HVB)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong Revenue GrowthRapid revenue expansion demonstrates strong demand across Centene’s government-sponsored and Marketplace businesses. Continued top-line growth can broaden operating scale, support investment in care-management capabilities, and provide a durable base for improving earnings if medical costs remain controlled.

Negative Factors

Volatile, Thin ProfitabilityProfitability has not yet demonstrated consistent durability despite strong revenue growth. The 2025 loss and low TTM operating margin indicate that medical utilization, execution, or other cost pressures can quickly erode earnings and limit the conversion of scale into shareholder returns.

Centene (0HVB) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: $34.88B
Dividend Yield: ―
Average Volume (3M): 4,802
Price to Earnings (P/E): 23.8
Beta (1Y): 0.27
Revenue Growth: 9.71%
EPS Growth: ―
Country: UK
Employees: 61,100
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Healthcare Plans

Centene Business Overview & Revenue Model

Company Description

Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The...

Centene Earnings Call Summary

Earnings Call Date:Oct 27, 2026(Q3-2026)|% Change Since:3.83%|Next Earnings Date:Feb 09, 2027

Earnings Call SentimentPositive

The call was strongly positive overall. Centene delivered a better-than-expected third quarter, raised 2026 adjusted EPS guidance from more than $4.80 to more than $5.20, reported strong Medicare and Marketplace performance, reached an earlier-than-expected Medicare Advantage breakeven target, reduced debt, and described multiple operating and cost-management improvements. The primary challenges were Medicaid membership declines and work-requirement-related acuity risks, expected Medicare Advantage membership contraction, Marketplace membership attrition and program-integrity costs, the planned commercial-group exit, and a likely PDP margin reset in 2027. Highlights significantly outweighed the lowlights.

Positive Updates

Third-Quarter Earnings Beat and Raised 2026 Outlook

Centene reported third-quarter adjusted diluted EPS of $0.58, ahead of previous expectations, on $45.1 billion in premium and service revenue. Consolidated HBR was 92.7%, better than expected, and full-year 2026 adjusted diluted EPS guidance was raised to more than $5.20 from more than $4.80. The improved outlook was attributed to continued Medicare strength, Marketplace pretax margin moving to the top of the prior 4.5% to 5.0% range, and lower interest expense with a midpoint of $610 million.

Negative Updates

Medicaid Membership Decline and Eligibility Headwinds

Medicaid ended the quarter with 11.9 million members, down 5.0% year to date. Centene expects full-year 2026 Medicaid membership to be down approximately 8% to 9% versus year-end 2025, with additional Q4 reductions tied to Florida CMS membership rolling off, OB3 eligibility terminations for legal noncitizens, and at least one state beginning work requirements.

Company Guidance

Centene raised 2026 adjusted diluted EPS guidance to >$5.20, with a full-year Medicaid HBR of approximately 93.5%, Medicaid membership down 8% to 9% year over year, a composite Medicaid rate of ~5%, Medicare Advantage reaching breakeven, PDP pretax margins in the mid- to high 3s, Marketplace pretax margin at the top of the previous 4.5% to 5.0% range, year-end Marketplace membership around 3.2 million, a full-year SG&A ratio midpoint of 7.2%, approximately $1.5 billion of investment and other income, and interest expense at a midpoint of $610 million; for 2027, the company expects to grow adjusted EPS relative to both the $4.70 jump off point and the revised $5.20 2026 guidance, with slight improvement in Medicaid HBR, Medicare Advantage better than breakeven, PDP membership growth, an improved SG&A rate, Medicaid membership attrition from OB 3, Medicare Advantage membership down year over year, Marketplace slight contraction, and an opening PDP margin expectation probably somewhere in 2% to 3% range.

Centene Risk Analysis

Centene disclosed 34 risk factors in its most recent earnings report. Centene reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Centene Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0HVB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OSCR	77Outperform	$10.33B	11.55	49.48%	―	54.77%	―
ELV	76Outperform	$92.83B	18.29	11.59%	1.60%	3.60%	-4.06%
CI	75Outperform	$79.88B	13.27	14.10%	2.05%	6.79%	-0.38%
HUM	58Neutral	$52.61B	43.02	6.70%	0.79%	22.02%	-3.07%
MOH	53Neutral	$10.77B	-343.03	-1.17%	―	-0.95%	-105.84%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

GB:0HVB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0HVB	Centene	70.55	34.55	95.97%
CI	Cigna	301.45	36.56	13.80%
HUM	Humana	446.31	212.62	90.98%
MOH	Molina Healthcare Inc	209.25	70.77	51.10%
ELV	Elevance Health, Inc.	429.48	107.60	33.43%
OSCR	Oscar Health, Inc.	32.11	18.16	130.18%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Centene AI Stock Analysis